10-Q: Shuttle Pharmaceuticals Holdings Reports First Quarter 2024 Results, Faces Going Concern Uncertainty

Shuttle Pharmaceuticals Holdings reported a net loss of $1.7 million for the first quarter of 2024 and is facing substantial doubt about its ability to continue as a going concern.

Summary

• Shuttle Pharmaceuticals Holdings reported a net loss of $1.7 million for the three months ended March 31, 2024, compared to a net loss of $0.97 million for the same period in 2023.
• The company had no revenue for the quarter.
• Research and development expenses decreased to $0.6 million from $0.9 million year-over-year, primarily due to the completion of drug product manufacturing.
• General and administrative expenses increased to $0.3 million from $0.25 million year-over-year, mainly due to a restricted stock-based grant.
• Legal and professional expenses increased to $0.47 million from $0.37 million year-over-year, primarily due to public filing requirements and financing-related work.
• The company's working capital was approximately $2.9 million as of March 31, 2024, down from $4.6 million at the end of 2023.
• The company's cash and cash equivalents were $1.4 million as of March 31, 2024, down from $2.6 million at the end of 2023.
• The company has a convertible note payable outstanding with covenants and cash payment requirements, which raises substantial doubt about its ability to continue as a going concern.
• Management is initiating a $4.5 million rights offering and has applied for a Small Business Innovation Research grant to secure additional funding.
• The company issued 625,573 shares of common stock to settle $235,200 of principal and $18,783 of interest on a convertible note.

Sentiment

Score: 3

Explanation: The document indicates significant financial challenges, including a substantial net loss, decreased cash reserves, and a going concern warning. While there are some positive developments in clinical trials, the overall financial outlook is concerning.

Positives

• The company completed the manufacturing of the active pharmaceutical ingredient for Ropidoxuridine.
• The company received FDA approval to begin the Phase II clinical trial for Ropidoxuridine.
• The company has completed the radiation biomarker project and the health disparities project.
• The company is actively seeking additional funding through a rights offering and a grant application.

Negatives

• The company reported a significant net loss of $1.7 million for the quarter.
• The company has no revenue.
• The company's cash reserves have decreased significantly.
• The company's working capital has decreased significantly.
• The company's convertible note payable includes covenants and cash payment requirements that raise doubts about its ability to continue as a going concern.
• The company's internal controls over financial reporting were deemed ineffective as of March 31, 2024.

Risks

• The company's ability to continue as a going concern is dependent on its ability to raise additional capital.
• The company's existing cash resources are not expected to be sufficient to fund operations and clinical trials for the next 12 months.
• The company's internal controls over financial reporting are ineffective.
• The company is subject to risks related to clinical trials, regulatory approvals, and intellectual property protection.
• The company's former auditor, BF Borgers CPA PC, has been denied the privilege of appearing or practicing before the SEC, requiring the company to re-audit its 2022 financial statements.

Future Outlook

The company is planning to commence its Phase II clinical study in the second quarter of 2024 and is seeking additional funding through a $4.5 million rights offering and a Small Business Innovation Research grant. The company's ability to continue as a going concern is dependent on its ability to raise additional capital.

Management Comments

• Management is in the process of initiating a $4.5 million rights offering.
• Management has submitted an application for a Small Business Innovation Research (SBIR) grant for non-dilutive funding.
• Management believes the company remains on track to commence its Phase II clinical study in the second quarter of 2024.

Industry Context

The company is operating in the competitive pharmaceutical industry, focusing on developing novel cancer therapies. The company's approach of combining radiation therapy with its proprietary drugs is aligned with the industry's trend of exploring combination therapies to improve patient outcomes. The company's reliance on external funding and the need for regulatory approvals are common challenges in the biotechnology sector.

Comparison to Industry Standards

• Shuttle Pharmaceuticals is a development-stage company, and its financial results are not directly comparable to established pharmaceutical companies with commercial products.
• The company's R&D spending is typical for a biotech company at its stage, but the lack of revenue is a significant concern.
• The company's reliance on convertible debt financing is common among early-stage biotech companies, but the high interest rates and complex terms can be risky.
• The company's need for additional capital is consistent with the industry's capital-intensive nature, but the uncertainty about its ability to raise funds is a major risk.
• Compared to companies like Novocure (NVCR) which also focuses on cancer treatment using devices, Shuttle is still in the early stages of clinical development and has not yet achieved commercialization. Novocure has a market cap of over $2 billion and has commercialized its Optune device for glioblastoma, while Shuttle is still in Phase II trials.
• Companies like Kura Oncology (KURA) are also developing HDAC inhibitors, but Kura has a more advanced pipeline and has reported positive clinical trial results. Kura has a market cap of over $1 billion, while Shuttle is still in the early stages of clinical development.
• Shuttle's financial position is weaker than many of its peers, with a significant net loss and limited cash reserves. Many other biotech companies have raised significant capital through equity offerings and have a longer cash runway.

Related Party Transactions

• The company had a manufacturing agreement with TCG GreenChem, Inc., where one of the company's independent directors is CEO and CSO.

Stakeholder Impact

• Shareholders face significant risk due to the company's financial instability and going concern uncertainty.
• Employees may be impacted by potential cost-cutting measures or the company's inability to continue operations.
• Customers and suppliers may be affected by the company's financial challenges and potential delays in product development.
• Creditors face increased risk due to the company's financial instability and potential inability to repay debts.

Next Steps

• The company plans to commence its Phase II clinical study in the second quarter of 2024.
• The company will proceed with the $4.5 million rights offering.
• The company will continue to seek non-dilutive funding through the SBIR grant application.
• The company will re-audit its 2022 financial statements due to the SEC order against its former auditor.

Key Dates

Keywords

Pharmaceuticals, Clinical Trials, Ropidoxuridine, Cancer Therapy, HDAC Inhibitors, Biotechnology, Financial Results, Going Concern, Rights Offering, SBIR Grant